Search

Displaying results 5111 - 5120 of 10000 in total
  1. Drug

    Darifenacin

    go.drugbank.com/drugs/DB00496
    ApprovedInvestigational

    This block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.

    Categories: Genito Urinary System and Sex Hormones, Drugs for Urinary Frequency and IncontinenceProducts: EMSELEX 15MG RET, EMSELEX 15MG RETARDTABL
  2. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  3. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  4. Drug

    Hycanthone

    go.drugbank.com/drugs/DB14061
    Experimental

    Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.

  5. Drug

    Desmoteplase

    go.drugbank.com/drugs/DB04925
    Investigational

    When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting. … Desmoteplase is a chemical in the saliva of vampire bats. It activates plasminogen to the serine protease, plasmin. Plasmin acts by breaking down fibrin blood clots.

    Categories: Enzymes and Coenzymes, Amino Acids, Peptides, and Proteins
  6. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

    Synonyms: N-(4-hydroxyphenyl)all-trans retinamideCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  8. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

  9. Drug

    ATG-Fresenius S

    go.drugbank.com/drugs/DB05320
    Investigational

    ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. … ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line.

  10. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.